After IFM buy, Novartis looks to more early stage biotech M&A

Allison DeAngelis
After IFM buy, Novartis looks to more early stage biotech M&A

After the gene therapy M&A; battles of late 2018, Novartis is looking to buy up more preclinical or early stage biotechs like Boston-based IFM Tre.